ITGR

Business Context and Reporting Period

Company: Greatbatch, Inc. (Note: Request metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 3, 2009
Business Overview: Greatbatch is a leading developer and manufacturer of critical products for medical devices (Cardiac Rhythm Management, Neuromodulation, Vascular Access, Orthopaedics) and electrochemical cells/battery packs for energy, security, and environmental monitoring. The company operates two reportable segments: Greatbatch Medical and Electrochem Solutions.

Key Financial Metrics

Note: Q1 2008 figures have been retroactively adjusted for the adoption of FSP APB 14-1 regarding convertible debt accounting.

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 14% year-over-year, driven by a 19% increase in the Greatbatch Medical segment (specifically CRM/Neuromodulation and Orthopaedic lines). This was partially offset by a 10% decline in the Electrochem segment due to a slowdown in energy markets.
• Profitability Turnaround: The company moved from an operating loss of $4.1 million in Q1 2008 to an operating income of $14.8 million in Q1 2009. This improvement is attributed to higher production volumes absorbing fixed costs, lower excess capacity, and the absence of inventory step-up amortization present in the prior year.
• Cost Structure: Cost of sales as a percentage of sales decreased by 9.7 percentage points to 68.4%. SG&A expenses as a percentage of sales decreased to 13.4%.
• Accounting Change: The company adopted FSP APB 14-1, requiring the separation of liability and equity components for convertible subordinated notes. This resulted in a retrospective restatement of 2008 figures, increasing reported interest expense and reducing prior period net loss.

Guidance, Outlook, and Risks

• 2009 Sales Outlook: Management expects full-year 2009 sales to range between $550 million and $600 million. This assumes continued growth faster than the underlying market, though risks include softening in orthopaedic and energy markets, delays in elective surgeries, and foreign exchange fluctuations.
• Consolidation Initiatives: The company is executing facility shutdowns and consolidations (e.g., Teterboro, Blaine, Exton) expected to cost between $14.2 million and $17.5 million total. Approximately $10.8 million has been incurred through April 3, 2009.
• Liquidity: Cash and cash equivalents were $15.1 million. The company has a $235 million revolving credit facility with $104 million available. Management believes cash flow from operations and available credit are sufficient to meet obligations, including potential put options on convertible notes due in 2010.
• Key Risks:
  • Customer Concentration: Four customers accounted for 59% of total sales in Q1 2009.
  • Foreign Currency: Significant operations in France, Mexico, and Switzerland expose the company to exchange rate risks. A 10% change in the USD could impact annual sales by approximately $10 million.
  • Legal Proceedings: An ongoing patent infringement appeal regarding the FlowGuard valved introducer requires royalty payments into an escrow fund ($1.1 million accrued as of April 3, 2009) pending the appeal outcome.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the top four customers who represent 59% of revenue.
• Working Capital Trends: Monitor the $162.6 million working capital balance, as management anticipates "working off" excess receivables and inventory levels in coming quarters.
• Consolidation Costs: Track the remaining $3.4 million to $6.7 million in expected costs for facility shutdowns and consolidations.
• Legal Escrow: Monitor the status of the Pressure Products patent infringement appeal and the associated escrow fund requirements.
• Debt Covenants: Confirm continued compliance with the credit facility's leverage ratio (max 5.00:1.00 through Sept 2009, then 4.50:1.00) and interest coverage ratio (min 3.00:1.00).